Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721695 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL721697 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL721694 | 1.00 | ALDH1A1 (0.34) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL716981 | 0.82 | KMT2A (0.32) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL716984 | 0.82 | KMT2A (0.32) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL716983 | 0.82 | KMT2A (0.32) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL716982 | 0.82 | KMT2A (0.32) | ALDH1A1MEN1MAPTKMT2ANPC1 | |
| SCHEMBL714885 | 0.81 | MAPT (0.48) | MEN1MAPTKMT2ANPC1GAA | |
| SCHEMBL2116469 | 0.81 | MAPT (0.48) | MEN1MAPTKMT2ANPC1GAA | |
| SCHEMBL2116471 | 0.81 | MAPT (0.48) | MEN1MAPTKMT2ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | ALDH1A1 3504/4885MEN1 3000/4885MAPT 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.